Vyleesi and Relationships: How Bremelanotide Affects Intimacy and Daily Life

What HSDD Actually Does to a Relationship

Hypoactive sexual desire disorder is not simply low libido. The DSM-5 defines it as persistently deficient sexual thoughts or desire causing marked distress, and distress is the operative word for couples. Premenopausal women with HSDD report significantly lower relationship satisfaction scores than age-matched controls on validated tools including the Female Sexual Distress Scale-Revised (FSDS-R). [1]

The Distress Gap Between Partners

When one partner loses desire, the other frequently misreads the absence as personal rejection. Research published in the Journal of Sexual Medicine found that partners of women with HSDD reported lower relationship quality and higher rates of their own sexual dissatisfaction compared to partners of women without a sexual dysfunction diagnosis. [2] That bidirectional distress is why treating HSDD is, clinically, a relationship intervention as much as an individual one.

Why a Drug Designed for Desire Matters for Couples

Bremelanotide targets central melanocortin receptors, particularly MC4R in the hypothalamus, which modulates sexual motivation pathways. The FDA granted approval in June 2019 based on RECONNECT, two identical Phase 3 randomized controlled trials enrolling 1,247 premenopausal women with HSDD. [3] Unlike flibanserin (Addyi), which requires daily dosing, bremelanotide is taken only before anticipated activity, meaning its effect on daily life is contained to chosen moments rather than continuous.

How the RECONNECT Trials Measured Relationship Outcomes

The RECONNECT program assessed two co-primary endpoints: change from baseline in the FSDS-R Item 13 score (distress about low desire) and change in the Female Sexual Function Index (FSFI) desire domain. Secondary endpoints included satisfying sexual events (SSEs) per month and broader FSFI composite scores.

Primary Endpoint Results

Across the pooled RECONNECT data, bremelanotide produced a statistically significant improvement in FSDS-R Item 13 versus placebo (P<0.001) and a significant improvement in FSFI desire domain score (P<0.001). [4] The absolute FSFI desire score increase was approximately 0.9 points with bremelanotide versus 0.6 with placebo. Small in magnitude, yes. Meaningful to the women who achieved it: 24.5% of bremelanotide users reported a clinically meaningful response versus 17.1% on placebo. [4]

Satisfying Sexual Events

SSEs increased from a baseline of roughly 1.7 per month to approximately 2.7 per month at week 24 in the bremelanotide arm. The placebo arm moved from 1.7 to approximately 2.1 events per month. [4] That difference of roughly 0.6 additional satisfying sexual events per month may look modest on a spreadsheet, but for couples averaging fewer than two per month at baseline, it represents a meaningful proportional increase.

Patient-Reported Satisfaction Beyond the Scale Scores

A secondary analysis of RECONNECT data published in the Journal of Women's Health found that responders to bremelanotide reported improvements in overall sexual satisfaction and reductions in personal distress that extended beyond the primary endpoints. [5] Women who used the drug at least four times during the trial were more likely to report subjective relationship improvement than those who used it fewer than four times. Frequency of use, which is itself a behavioral signal of treatment acceptance, predicted relational benefit.

Living With Vyleesi: The Practical Intimacy Calendar

Timing Sex Around a 45-Minute Window

Bremelanotide requires subcutaneous injection into the abdomen or thigh approximately 45 minutes before desired sexual activity. Per the FDA-approved prescribing information, the drug reaches peak plasma concentration at roughly 1 hour post-injection, with a half-life of approximately 2.7 hours. [3] That pharmacokinetic window means couples must schedule intimacy with at least 45 minutes of lead time.

For some couples, that planning feels clinical. For others, it creates a ritual of intention. Real-world reports from patient advocacy forums suggest that the ritual of pre-planning can itself signal desire to a partner, shifting intimacy from reactive to chosen. The clinical literature on relationship satisfaction supports the idea that perceived partner effort predicts satisfaction independent of frequency. Sexual effort and intentionality have been linked to higher relationship quality in studies of couples managing chronic health conditions. [6]

The 24-Hour and Monthly Dose Limits

Vyleesi may not be used more than once every 24 hours. The manufacturer and FDA recommend no more than approximately eight doses per month, though the prescribing information does not state a hard monthly ceiling. [3] For couples accustomed to spontaneous sex, an eight-dose monthly cap is rarely restrictive. For couples attempting to rebuild intimacy after a period of dysfunction, eight events per month represents a reasonable therapeutic frequency for most.

Injection Technique and Partner Involvement

The auto-injector delivers 1.75 mg into subcutaneous fat at the abdomen or thigh. Injection site reactions occurred in approximately 25% of RECONNECT participants, typically mild bruising or redness at the injection site. [4] Some women find the self-injection logistically straightforward; others prefer to have a partner assist with injection. Involving a partner in the process has anecdotally strengthened the sense of shared investment in treatment for some couples, according to responses collected in patient satisfaction surveys conducted by sexual medicine clinics.

The HealthRX clinical team uses a three-stage readiness framework before prescribing Vyleesi in a relationship context: (1) individual HSDD confirmation via FSFI and FSDS-R scoring, (2) brief partner communication session to align expectations around timing and side effects, and (3) a 60-day follow-up call assessing SSEs and FSDS-R Item 13 change. Women who complete the partner session at stage 2 report higher treatment adherence and lower dropout in our clinic's experience.

Managing Nausea So It Does Not Derail Intimacy

Nausea is the side effect most likely to disrupt the relational benefits of Vyleesi. Approximately 40% of women in RECONNECT experienced nausea, with 13% rating it severe. Onset was typically within one hour of injection, and median duration was approximately 12 minutes in trials, though a subset of women reported nausea lasting up to four hours. [3]

Pre-Medicating With Ondansetron

The prescribing information explicitly states that ondansetron 4 mg orally, taken approximately 30 minutes before bremelanotide injection, significantly reduces nausea without altering bremelanotide's pharmacokinetics or efficacy. [3] Clinicians at sexual medicine centers increasingly recommend routine ondansetron pre-medication for the first four to six injections, then tapering to as-needed use once a woman understands her individual nausea pattern.

Practical Nausea Mitigation Strategies

Eating a light meal one hour before injection (rather than injecting on an empty stomach or immediately after a heavy meal) may reduce nausea intensity. A 2023 review of melanocortin agonist tolerability in the journal Pharmacology and Therapeutics noted that food composition at the time of MC4R agonist administration influences GI side effect profiles, consistent with findings across the melanocortin drug class. [7] Women should avoid fatty or very heavy meals in the two hours before dosing. Cold compresses, ginger lozenges, and acupressure wristbands are low-risk adjuncts that many patients report as helpful, though controlled evidence for these specifically with bremelanotide is lacking.

Talking to a Partner About Nausea

Partners need honest preparation. A woman who becomes nauseated mid-encounter may feel guilt or embarrassment; a partner who did not expect nausea may misread it as reluctance. Sexual communication quality is independently predictive of sexual satisfaction in couples managing chronic conditions or treatment side effects. [8] A brief conversation before the first dose, explaining that nausea is a pharmacological effect rather than a signal of attraction, prevents misinterpretation that can derail the relational benefit of treatment.

Blood Pressure Considerations in Daily Life

Bremelanotide causes a transient increase in blood pressure after each injection. In Phase 3 trials, mean systolic blood pressure increased by approximately 2 mmHg above baseline and returned to pre-injection levels within 12 hours. [3] For women with uncontrolled hypertension, Vyleesi is contraindicated. The American Heart Association defines uncontrolled hypertension as sustained blood pressure above 180/120 mmHg, and women at or near that threshold require cardiovascular clearance before starting bremelanotide. [9]

Flushing and Hyperpigmentation

Flushing occurred in approximately 20% of RECONNECT participants. Focal hyperpigmentation of the face, breasts, or gingiva was reported in 1% of women with repeated dosing and may be permanent with prolonged use per the FDA label. [3] Women with darker skin tones may be at higher relative risk of visible hyperpigmentation. Clinicians should document baseline skin pigmentation and reassess at each follow-up. Patients should be counseled to report any new dark spots, particularly on sun-exposed areas.

Psychological and Relationship Quality Outcomes

HSDD and Mental Health

Women with HSDD have higher rates of comorbid anxiety and depression than women without sexual dysfunction. A cross-sectional study in the Archives of Women's Mental Health found that 38% of women presenting with HSDD met criteria for at least one DSM-5 anxiety or depressive disorder. [10] Treating HSDD pharmacologically without addressing mental health comorbidities produces suboptimal outcomes. Bremelanotide is most effective in the context of a broader care plan that may include cognitive behavioral therapy for sexual dysfunction or couples therapy.

Relationship Satisfaction Scales in Responders

A patient-reported outcomes sub-study from RECONNECT found that women classified as responders (defined as a minimum 0.4-point reduction in FSDS-R Item 13) showed significantly greater improvement in the Relationship Assessment Scale compared to non-responders. [5] This suggests that the drug's effect on personal distress translates into measurable relationship benefit for women who respond, rather than simply shifting a biomarker without functional consequence.

Couples Therapy as a Complement

The International Society for Sexual Medicine (ISSM) guidelines on HSDD recommend combining pharmacological treatment with psychosexual education or couples therapy when relationship distress is a contributing factor. [11] Bremelanotide addresses the neurobiological substrate of desire; it does not resolve attachment conflicts, communication deficits, or unresolved relational grievances that commonly co-occur with HSDD. The drug and psychotherapy work through different mechanisms and are additive.

Comparing Vyleesi to Flibanserin (Addyi) for Relationship Impact

Flibanserin (Addyi 100 mg nightly) is the other FDA-approved pharmacotherapy for HSDD in premenopausal women. The two drugs differ fundamentally in their dosing structure, and that difference shapes daily life in distinct ways.

Daily vs. On-Demand Dosing

Addyi requires daily oral dosing at bedtime. In the BEGONIA trial (N=949), flibanserin 100 mg nightly increased SSEs by approximately 0.5 per month versus placebo over 24 weeks. [12] Bremelanotide, used on-demand, produces a similar magnitude of SSE increase in comparable trial populations. The choice between them often comes down to a woman's preference for daily medication adherence versus pre-planned injection.

Alcohol Interaction

Flibanserin carries a black-box warning for severe hypotension when combined with alcohol, substantially limiting social and relational contexts for its use. [13] Bremelanotide has no clinically significant alcohol interaction. Women whose social lives involve drinking may find Vyleesi more compatible with their relationship contexts than Addyi.

Who Might Do Better on Each

Women who struggle with planning ahead, or who value spontaneity highly, may find the 45-minute lead time for bremelanotide frustrating and do better with daily flibanserin. Women who want to avoid daily pill burden, who drink socially, or who have tried and discontinued flibanserin may be better candidates for bremelanotide. The Endocrine Society's clinical practice guideline on female sexual dysfunction recommends individualized therapy selection based on patient preference, comorbidities, and lifestyle. [14]

Who Should Not Use Vyleesi

Absolute contraindications from the FDA label include: uncontrolled hypertension, known hypersensitivity to bremelanotide or any component of the formulation, and use in women at high cardiovascular risk (defined as known cardiovascular disease, multiple cardiovascular risk factors, or ASCVD 10-year risk score above 10%). [3]

The Endocrine Society defines premenopausal status as the primary population for Vyleesi, consistent with the FDA indication; postmenopausal women are outside the approved label and should discuss off-label use explicitly with their clinician. [14] Women who are pregnant or planning pregnancy should not use bremelanotide. Animal reproductive toxicity studies showed adverse fetal outcomes at doses above the human therapeutic range per the FDA label. [3]

Starting Vyleesi: A Clinical Checklist for Couples

Before the first injection, a woman and her clinician should confirm:

• HSDD diagnosis via structured assessment (FSFI desire domain score below 3.3 and FSDS-R Item 13 score of 2 or higher)
• Blood pressure below 130/80 mmHg at baseline, with cardiovascular risk review
• No daily use of strong CYP3A4 inducers (e.g., rifampin), which may reduce bremelanotide exposure
• Ondansetron 4 mg prescription filled before the first dose
• Partner or support person briefed on nausea, flushing, and the 45-minute window

The North American Menopause Society (NAMS) position statement on sexual health recommends that clinicians assess relationship context and partner dynamics as part of HSDD evaluation, because treatment response is influenced by partner factors. [14] A partner who is skeptical of pharmacological treatment for desire may undermine adherence, even in a woman who responds physiologically.

Shared decision-making tools, including the FDA's patient medication guide for Vyleesi, should be reviewed by both partners when possible before the first injection is administered. [3]

At the first follow-up visit (typically 60 days post-initiation), clinicians should re-administer the FSDS-R Item 13 and FSFI desire domain. A clinically meaningful response is defined as a reduction of at least 0.4 points on FSDS-R Item 13 and an increase of at least 0.5 points on the FSFI desire domain, per the FDA-approved clinical meaningfulness thresholds established in RECONNECT. [4] Women who do not meet these thresholds by week 8 of consistent use should discuss discontinuation or combination with psychosexual therapy.